Intellia Therapeutics Inc (NASDAQ:NTLA) shot up 11.1% on Monday . The company traded as high as $29.28 and last traded at $29.01. 1,127,733 shares traded hands during trading, an increase of 23% from the average session volume of 920,335 shares. The stock had previously closed at $26.12.
A number of research firms recently weighed in on NTLA. BidaskClub raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 9th. Oppenheimer reaffirmed a “hold” rating on shares of Intellia Therapeutics in a report on Monday, December 18th. Credit Suisse Group raised their price target on Intellia Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. TheStreet cut Intellia Therapeutics from a “c-” rating to a “d” rating in a report on Thursday, December 14th. Finally, ValuEngine cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Intellia Therapeutics currently has an average rating of “Hold” and a consensus target price of $30.17.
The company has a market cap of $1,230.00 and a P/E ratio of -18.72.
Large investors have recently bought and sold shares of the company. Nationwide Fund Advisors boosted its position in shares of Intellia Therapeutics by 117.7% in the 2nd quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock worth $129,000 after purchasing an additional 4,351 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in shares of Intellia Therapeutics in the 4th quarter worth $146,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Intellia Therapeutics in the 2nd quarter worth $167,000. The Manufacturers Life Insurance Company boosted its position in shares of Intellia Therapeutics by 451.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock worth $212,000 after purchasing an additional 10,825 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Intellia Therapeutics in the 4th quarter worth $230,000. Institutional investors and hedge funds own 57.44% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.